Predictive Biochemical Factors for Pre-eclampsia in Early Pregnancy

Lorna   Muscat   Baron; Byron      Baron
Abstract

Pre-eclampsia (PE) is one of the major pregnancy complications, affecting up to 10 % of all pregnancies in some regions of the world. The clinical diagnosis, characterised by hypertension and proteinuria often late during pregnancy, with the added inability to treat (other than delivery), can lead to significant morbidity and mortality in both mother and unborn foetus. Moreover, as yet, only low dose aspirin administration is accepted as a preventive measure for PE. This puts more pressure to identify diagnostic and prognostic biomarkers of PE from blood or urine for the non-invasive screening of pregnant women before pregnancy becomes complicated. Over the years, a number of DNA and protein molecules, such as cell-free DNA, VEGF, sFLT1, PlGF, PP-13, ADMA, and several other biomarkers, have been linked to specific pathophysiological observations and proposed as predictive markers for PE. However, their reliability and reproducibility have been put to the test by numerous studies. The aim of this review is to cover the key clinical and biochemical features of pregnancies complicated by PE and evaluate the robustness of data gathered from various studies in order to better understand the link between the proposed biomarkers and the development of PE so as to better quantify their relevance in diagnostic or prognostic applications. The overall goal is to use such biomarkers for earlier detection, better molecular monitoring, and, where possible, lessening of symptoms, hopefully leading to a reduction in the yearly PE-related deaths worldwide.
Keywords: Pre-eclampsia, pregnancy complications, endothelial dysfunction, biomarkers, diagnosis, prognosis.
Graphical Abstract

[1]
Boeldt DS, Bird IM. Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. J Endocrinol  2017; 232(1): R27-44.
 [http://dx.doi.org/10.1530/JOE-16-0340] [PMID: 27729465]

[2]
Grill S, Rusterholz C, Zanetti-Dällenbach R, et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol  2009; 7(1): 70.
 [http://dx.doi.org/10.1186/1477-7827-7-70] [PMID: 19602262]

[3]
Portelli M, Baron B. Clinical presentation of preeclampsia and the diagnostic value of proteins and their methylation products as biomarkers in pregnant women with preeclampsia and their newborns. J Pregnancy  2018; 2018: 2632637.
 [http://dx.doi.org/10.1155/2018/2632637] [PMID: 30050697]

[4]
Program, National High Blood Pressure Education.; Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol  2000; 183(1): S1-S22.
 [http://dx.doi.org/10.1067/mob.2000.107928] [PMID: 10920346]

[5]
ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol  2002; 99(1): 159-67.
 [PMID: 16175681]

[6]
Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that preeclampsia is more than one disease.  Obstet Gynecol  2014; 210(1): 66.

[7]
Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician  2004; 70(12): 2317-24.
 [PMID: 15617295]

[8]
Burton GJ, Fowden AL. The placenta: A multifaceted, transient organ. Philos Trans R Soc Lond B Biol Sci  2015; 370(1663): 20140066.
 [http://dx.doi.org/10.1098/rstb.2014.0066] [PMID: 25602070]

[9]
Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension  2013; 62(4): 666-73.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.00588] [PMID: 23897068]

[10]
Portelli M, Baron B. Biochemical dysregulation of pre-eclampsia and gestational diabetes mellitus. In: Sharma N, Ed.  Prediction of Maternal and Fetal Syndrome of Preeclampsia. London, UK: IntechOpen 2019.
 [http://dx.doi.org/10.5772/intechopen.85843]

[11]
Maynard SE, Min JY, Merchan J, et al. Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest  2003; 111(5): 649-58.
 [http://dx.doi.org/10.1172/JCI17189] [PMID: 12618519]

[12]
Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med  2006; 12(6): 642-9.
 [http://dx.doi.org/10.1038/nm1429] [PMID: 16751767]

[13]
Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth  2009; 9(1): 8.
 [http://dx.doi.org/10.1186/1471-2393-9-8] [PMID: 19245695]

[14]
Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab  2004; 89(2): 770-5.
 [http://dx.doi.org/10.1210/jc.2003-031244] [PMID: 14764795]

[15]
Gai W, Sun K. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes (Basel)  2019; 10(1): 32.
 [http://dx.doi.org/10.3390/genes10010032] [PMID: 30634483]

[16]
Kim SY, Kim HJ, Park SY, Han YJ, Choi JS, Ryu HM. Early Prediction of Hypertensive Disorders of Pregnancy Using Cell-Free Fetal DNA, Cell-Free Total DNA, and Biochemical Markers. Fetal Diagn Ther  2016; 40(4): 255-62.
 [http://dx.doi.org/10.1159/000444524] [PMID: 26998901]

[17]
Kolarova TR, Gammill HS, Nelson JL, Lockwood CM, Shree R. At Preeclampsia Diagnosis, Total Cell-Free DNA Concentration is Elevated and Correlates With Disease Severity. J Am Heart Assoc  2021; 10(15): e021477.
 [http://dx.doi.org/10.1161/JAHA.121.021477] [PMID: 34310191]

[18]
Silver RM, Myatt L, Hauth JC, et al. Cell-free total and fetal DNA in first trimester maternal serum and subsequent development of preeclampsia. Am J Perinatol  2017; 34(2): 191-8.
 [PMID: 27398706]

[19]
Chua S, Wilkins T, Sargent I, Redman C. Trophoblast deportation in pre-eclamptic pregnancy. Br J Obstet Gynaecol  1991; 98(10): 973-9.
 [http://dx.doi.org/10.1111/j.1471-0528.1991.tb15334.x] [PMID: 1751443]

[20]
DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol  1999; 155(1): 293-301.
 [http://dx.doi.org/10.1016/S0002-9440(10)65123-1] [PMID: 10393861]

[21]
Lun FM, Chiu RW, Chan KC, Leung TY, Lau TK, Lo YM. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem  2008; 54(10): 1664-72.
 [http://dx.doi.org/10.1373/clinchem.2008.111385] [PMID: 18703764]

[22]
Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med  2010; 2(61): 61ra91.
 [http://dx.doi.org/10.1126/scitranslmed.3001720] [PMID: 21148127]

[23]
Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem  2001; 47(1): 137-9.
 [http://dx.doi.org/10.1093/clinchem/47.1.137] [PMID: 11148193]

[24]
Holzgreve W, Ghezzi F, Di Naro E, Gänshirt D, Maymon E, Hahn S. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol  1998; 91(5 Pt 1): 669-72.
 [PMID: 9572208]

[25]
Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH. Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. Hum Reprod  2000; 15(7): 1624-8.
 [http://dx.doi.org/10.1093/humrep/15.7.1624] [PMID: 10875878]

[26]
Kilian O, Alt V, Heiss C, et al. New blood vessel formation and expression of VEGF receptors after implantation of platelet growth factor-enriched biodegradable nanocrystalline hydroxyapatite. Growth Factors  2005; 23(2): 125-33.
 [http://dx.doi.org/10.1080/08977190500126306] [PMID: 16019434]

[27]
Demir R, Kayisli UA, Seval Y, et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: Differences between placental vasculogenesis and angiogenesis. Placenta  2004; 25(6): 560-72.
 [http://dx.doi.org/10.1016/j.placenta.2003.11.011] [PMID: 15135240]

[28]
Kurtoglu E, Avci B, Kokcu A, et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med  2016; 29(12): 1987-92.
 [http://dx.doi.org/10.3109/14767058.2015.1072157] [PMID: 26333278]

[29]
Gaber K, Hamdy E, Hanafy A. Soluble endoglin as a new marker for prediction of pre-eclampsia in early pregnancy. Middle East Fertil Soc J  2010; 15(1): 42-6.
 [http://dx.doi.org/10.1016/j.mefs.2010.03.009]

[30]
Bersinger NA, Ødegård RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand  2004; 83(1): 37-45.
 [http://dx.doi.org/10.1111/j.1600-0412.2004.00277.x] [PMID: 14678084]

[31]
Noorbakhsh M, Kianpour M, Nematbakhsh M. Serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and nitric oxide metabolite levels in preeclampsia patients. ISRN Obstet Gynecol  2013; 2013: 104213.

[32]
Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: An in silico model. Am J Physiol Heart Circ Physiol  2010; 298(6): H2174-91.
 [http://dx.doi.org/10.1152/ajpheart.00365.2009] [PMID: 20382861]

[33]
Eleuterio NM, Palei AC, Rangel Machado JS, Tanus-Santos JE, Cavalli RC, Sandrim VC. Correlations between circulating levels of adipokines and anti-angiogenic factors in women with BMI <30 and a late-onset preeclampsia. Hypertens Pregnancy  2014; 33(1): 72-80.
 [http://dx.doi.org/10.3109/10641955.2013.837174] [PMID: 24380505]

[34]
Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn  2009; 29(5): 464-70.
 [http://dx.doi.org/10.1002/pd.2203] [PMID: 19242927]

[35]
Bian Z, Shixia C, Duan T. First-trimester maternal serum levels of sFLT1, PGF and ADMA predict preeclampsia. PLoS One  2015; 10(4): e0124684.
 [http://dx.doi.org/10.1371/journal.pone.0124684] [PMID: 25906026]

[36]
Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med  2006; 355(10): 992-1005.
 [http://dx.doi.org/10.1056/NEJMoa055352] [PMID: 16957146]

[37]
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble FMS-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther  2014; 35(4): 240-8.
 [http://dx.doi.org/10.1159/000359968] [PMID: 24853452]

[38]
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30–34 weeks’ gestation. Obstet Gynecol  2016; 215(1): 87.

[39]
Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand  2010; 89(1): 143-6.
 [http://dx.doi.org/10.3109/00016340903289892] [PMID: 20021269]

[40]
Widmer M, Cuesta C, Khan KS, et al. Accuracy of angiogenic biomarkers at 20weeks’ gestation in predicting the risk of pre-eclampsia: A WHO multicentre study. Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health  2015; 5(4): 330-8.
 [http://dx.doi.org/10.1016/j.preghy.2015.09.004] [PMID: 26597750]

[41]
Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res  2011; 1(2): 265-74.
 [PMID: 21969185]

[42]
Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med  2004; 350(7): 672-83.
 [http://dx.doi.org/10.1056/NEJMoa031884] [PMID: 14764923]

[43]
Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet  2012; 285(2): 417-22.
 [http://dx.doi.org/10.1007/s00404-011-1960-4] [PMID: 21735190]

[44]
Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: Markers for identification of women destined to develop early-onset pre-eclampsia. BJOG  2010; 117(11): 1384-9.
 [http://dx.doi.org/10.1111/j.1471-0528.2010.02690.x] [PMID: 20840693]

[45]
Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med  2008; 21(1): 9-23.
 [http://dx.doi.org/10.1080/14767050701830480] [PMID: 18175241]

[46]
Karumanchi SA. Angiogenic factors in preeclampsia: From diagnosis to therapy. Hypertension  2016; 67(6): 1072-9.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.06421] [PMID: 27067718]

[47]
Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (Pl-GF) in preeclampsia among high risk pregnancies. PLoS One  2010; 5(10): e13263.
 [http://dx.doi.org/10.1371/journal.pone.0013263] [PMID: 20948996]

[48]
Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation  2012; 125(7): 911-9.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.111.054361] [PMID: 22261192]

[49]
Baltajian K, Bajracharya S, Salahuddin S, et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Obstet Gynecol  2016; 215(1): 89.
 [http://dx.doi.org/10.1016/j.ajog.2016.01.168]

[50]
Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J  2003; 17(9): 984-92.
 [http://dx.doi.org/10.1096/fj.02-0634rev] [PMID: 12773481]

[51]
Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F, AtashAbParvar A. accuracy of soluble endoglin for diagnosis of preeclampsia and its severity. Iran Biomed J  2017; 21(5): 312-30.
 [http://dx.doi.org/10.18869/acadpub.ibj.21.5.312] [PMID: 28558439]

[52]
Wu CC, Bohr DF. Role of endothelium in the response to endothelin in hypertension. Hypertension  1990; 16(6): 677-81.
 [http://dx.doi.org/10.1161/01.HYP.16.6.677] [PMID: 2246034]

[53]
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature  1988; 332(6163): 411-5.
 [http://dx.doi.org/10.1038/332411a0] [PMID: 2451132]

[54]
Haynes WG, Webb DJ. The endothelin family of peptides: Local hormones with diverse roles in health and disease? Clin Sci (Lond)  1993; 84(5): 485-500.

[55]
Hosoda K, Nakao K, Hiroshi-Arai , et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett  1991; 287(1-2): 23-6.
 [http://dx.doi.org/10.1016/0014-5793(91)80007-P] [PMID: 1652463]

[56]
George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: Therapeutic implications. Curr Opin Nephrol Hypertens  2012; 21(2): 157-62.
 [http://dx.doi.org/10.1097/MNH.0b013e328350094b] [PMID: 22257796]

[57]
Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension  2001; 37(2 Pt 2): 485-9.
 [http://dx.doi.org/10.1161/01.HYP.37.2.485] [PMID: 11230323]

[58]
Nishikawa S, Miyamoto A, Yamamoto H, Ohshika H, Kudo R. The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia. Life Sci  2000; 67(12): 1447-54.
 [http://dx.doi.org/10.1016/S0024-3205(00)00736-0] [PMID: 10983841]

[59]
Maltaris T, Scalera F, Schlembach D, et al. Increased uterine arterial pressure and contractility of perfused swine uterus after treatment with serum from pre-eclamptic women and endothelin-1. Clin Sci (Lond)  2005; 109(2): 209-15.

[60]
Baksu B, Davas I, Baksu A, Akyol A, Gulbaba G. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. Int J Gynaecol Obstet  2005; 90(2): 112-7.
 [http://dx.doi.org/10.1016/j.ijgo.2005.04.018] [PMID: 16005006]

[61]
Di Iorio R, Marinoni E, Letizia C, Alò P, Villaccio B, Cosmi EV. Adrenomedullin, a new vasoactive peptide, is increased in preeclampsia. Hypertension  1998; 32(4): 758-63.
 [http://dx.doi.org/10.1161/01.HYP.32.4.758] [PMID: 9774376]

[62]
Senna AA, Zedan M, El-Salam GE, El-Mashad AI. Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J Med  2008; 10(2): 29.
 [PMID: 18382699]

[63]
Kraus D, Feng L, Heine RP, Brown H, Murtha A, Grotegut C. 43: Smoking and preeclamspia protection: Cigarette smoke increases placental adrenomedullin expression and improves trophoblast invasion via the adrenomedullin pathway. Am J Obstet Gynecol  2013; 208(1): S26.
 [http://dx.doi.org/10.1016/j.ajog.2012.10.217]

[64]
Lawrence JB, Oxvig C, Overgaard MT, et al. The Insulin-like Growth Factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA  1999; 96(6): 3149-53.
 [http://dx.doi.org/10.1073/pnas.96.6.3149] [PMID: 10077652]

[65]
Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.  Advances in clinical chemistry.  Elsevier 2014; pp. 169-209.

[66]
Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther  2009; 25(3): 320-7.
 [http://dx.doi.org/10.1159/000235878] [PMID: 19776595]

[67]
Luewan S, Teja-Intr M, Sirichotiyakul S, Tongsong T. Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia. Singapore Med J  2018; 59(1): 55-9.
 [http://dx.doi.org/10.11622/smedj.2017034] [PMID: 28451695]

[68]
Saxena AR, Seely EW, Rich-Edwards JW, Wilkins-Haug LE, Karumanchi SA, McElrath TF. First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth  2013; 13(1): 85.
 [http://dx.doi.org/10.1186/1471-2393-13-85] [PMID: 23557166]

[69]
Moslemi Zadeh N, Naghshvar F, Peyvandi S, Gheshlaghi P. PP13 and PAPP-A in the first and second trimesters: Predictive factors for preeclampsia? ISRN Obstetrics and Gynecology  2012; 263871.

[70]
Nanda S, Yu CK, Giurcaneanu L, Akolekar R, Nicolaides KH. Maternal serum adiponectin at 11-13 weeks of gestation in preeclampsia. Fetal Diagn Ther  2011; 29(3): 208-15.
 [http://dx.doi.org/10.1159/000322402] [PMID: 21266793]

[71]
Odibo AO, Zhong Y, Goetzinger KR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta  2011; 32(8): 598-602.
 [http://dx.doi.org/10.1016/j.placenta.2011.05.006] [PMID: 21652068]

[72]
Atis A, Aydin Y, Basol E, Kaleli S, Turgay F, Goker N. PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome. Arch Gynecol Obstet  2012; 285(1): 45-9.
 [http://dx.doi.org/10.1007/s00404-011-1912-z] [PMID: 21533533]

[73]
Than NG, Pick E, Bellyei S, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem  2004; 271(6): 1065-78.
 [http://dx.doi.org/10.1111/j.1432-1033.2004.04004.x] [PMID: 15009185]

[74]
Hutter S, Knabl J, Andergassen U, et al. Placental expression patterns of galectin-1, galectin-2, galectin-3 and galectin-13 in cases of intrauterine growth restriction (IUGR). Int J Mol Sci  2016; 17(4): 523.
 [http://dx.doi.org/10.3390/ijms17040523] [PMID: 27070577]

[75]
Sahraravand M, Järvelä IY, Laitinen P, Tekay AH, Ryynänen M. The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy. Placenta  2011; 32(12): 999-1003.
 [http://dx.doi.org/10.1016/j.placenta.2011.10.005] [PMID: 22015022]

[76]
Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Obstet Gynecol  2007; 197(1): 35.

[77]
De Villiers CP, Hedley PL, Placing S, et al. Placental Protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia. Clin Chem Lab Med  2017; 56(1): 65-74.
 [http://dx.doi.org/10.1515/cclm-2017-0356] [PMID: 28704180]

[78]
De Muro P, Capobianco G, Lepedda AJ, et al. Plasma PP13 and urinary GAGs/PGs as early markers of pre-eclampsia. Arch Gynecol Obstet  2016; 294(5): 959-65.
 [http://dx.doi.org/10.1007/s00404-016-4111-0] [PMID: 27161490]

[79]
Burger O, Pick E, Zwickel J, et al. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta  2004; 25(7): 608-22.
 [http://dx.doi.org/10.1016/j.placenta.2003.12.009] [PMID: 15193867]

[80]
Ali FT, Ibrahim AM, Hassan NS, Soliman RM. Placental protein 13, galectin 14 and pentraxin 3 for prediction of pre-eclampsia in Egyptian patients. Int J Med Sci Public Health  2018; 7(6): 427-34.

[81]
Gadde R, Dayanand C, Sheela SR. Placental protein 13 and asymmetric dimethyl arginine for early assessment of preeclampsia. Biomed Res  2019; 30(2): 319-24.

[82]
Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol  2007; 29(2): 128-34.
 [http://dx.doi.org/10.1002/uog.3876] [PMID: 17149788]

[83]
Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn  2009; 29(12): 1103-8.
 [http://dx.doi.org/10.1002/pd.2375] [PMID: 19777530]

[84]
Namwanje M, Brown CW. Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harb Perspect Biol  2016; 8(7): a021881.
 [http://dx.doi.org/10.1101/cshperspect.a021881] [PMID: 27328872]

[85]
Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab  1997; 82(5): 1557-60.
 [http://dx.doi.org/10.1210/jcem.82.5.3934] [PMID: 9141549]

[86]
Yu J, Shixia CZ, Wu Y, Duan T. Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol  2011; 37(5): 528-33.
 [http://dx.doi.org/10.1002/uog.8800] [PMID: 20737451]

[87]
Yu L, Li D, Liao QP, et al. High levels of activin A detected in preeclamptic placenta induce trophoblast cell apoptosis by promoting nodal signaling. J Clin Endocrinol Metab  2012; 97(8): E1370-9.
 [http://dx.doi.org/10.1210/jc.2011-2729] [PMID: 22685232]

[88]
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH. Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia. J Matern Fetal Neonatal Med  2013; 26(8): 733-7.
 [http://dx.doi.org/10.3109/14767058.2012.755167] [PMID: 23205865]

[89]
Ree PH, Hahn WB, Chang SW, et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. Fetal Diagn Ther  2011; 29(4): 280-6.
 [http://dx.doi.org/10.1159/000322742] [PMID: 21252475]

[90]
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn  2009; 29(8): 753-60.
 [http://dx.doi.org/10.1002/pd.2279] [PMID: 19412915]

[91]
Phupong V, Paiwattananupant K, Honsawek S. Inhibin A levels and severity of preeclampsia. Arch Gynecol Obstet  2009; 280(2): 183-6.
 [http://dx.doi.org/10.1007/s00404-008-0886-y] [PMID: 19107499]

[92]
Shen Z, Cai LY, Suprapto IS, Shenoy P, Zhou X. Placental and maternal serum inhibin A in patients with preeclampsia and small- for-gestational-age. J Obstet Gynaecol Res  2011; 37(10): 1290-6.
 [http://dx.doi.org/10.1111/j.1447-0756.2010.01513.x] [PMID: 21535305]

[93]
Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf)  2012; 76(1): 2-11.

[94]
Eleuterio NM, Palei AC, Rangel Machado JS, Tanus-Santos JE, Cavalli RC, Sandrim VC. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant. Pregnancy Hypertens  2015; 5(2): 205-8.
 [http://dx.doi.org/10.1016/j.preghy.2015.03.001] [PMID: 25943646]

[95]
Eleuterio NM, Palei AC, Rangel Machado JS, Tanus-Santos JE, Cavalli RC, Sandrim VC. Relationship between adiponectin and nitrite in healthy and preeclampsia pregnancies. Clin Chim Acta  2013; 423: 112-5.
 [http://dx.doi.org/10.1016/j.cca.2013.04.027] [PMID: 23643962]

[96]
Abd-Alaleem DI, Attiaa KI, Khalefa AA, Ahmad RA. Adiponectin levels in serum of women with preeclampsia. East Mediterr Health J  2011; 17(7): 575-81.
 [http://dx.doi.org/10.26719/2011.17.7.575] [PMID: 21972480]

[97]
Song Y, Gao J, Qu Y, Wang S, Wang X, Liu J. Serum levels of leptin, adiponectin and resistin in relation to clinical characteristics in normal pregnancy and preeclampsia. Clin Chim Acta  2016; 458: 133-7.
 [http://dx.doi.org/10.1016/j.cca.2016.04.036] [PMID: 27154800]

[98]
Thagaard IN, Hedley PL, Holm JC, et al. Leptin and Adiponectin as markers for preeclampsia in obese pregnant women, a cohort study. Pregnancy Hypertens  2019; 15: 78-83.
 [http://dx.doi.org/10.1016/j.preghy.2018.12.002] [PMID: 30825932]

[99]
Salimi S, Farajian-Mashhadi F, Naghavi A, et al. Different profile of serum leptin between early onset and late onset preeclampsia. Dis Markers  2014; 2014: 628476.
 [http://dx.doi.org/10.1155/2014/628476] [PMID: 24591763]

[100]
Khosrowbeygi A, Ahmadvand H. Positive correlation between serum levels of adiponectin and homocysteine in pre-eclampsia. J Obstet Gynaecol Res  2013; 39(3): 641-6.
 [http://dx.doi.org/10.1111/j.1447-0756.2012.02015.x] [PMID: 23106812]

[101]
Taylor BD, Ness RB, Olsen J, et al. Serum leptin measured in early pregnancy is higher in women with preeclampsia compared with normotensive pregnant women. Hypertension  2015; 65(3): 594-9.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03979] [PMID: 25510827]

[102]
El Shahat AM, Ahmed AB, Ahmed MR, Mohamed HS. Maternal serum leptin as a marker of preeclampsia. Arch Gynecol Obstet  2013; 288(6): 1317-22.
 [http://dx.doi.org/10.1007/s00404-013-2915-8] [PMID: 23771185]

[103]
Doster Y, Cetinkaya Demir B, Atalay MA, Durusoy EE, Kucukkomurcu S. The possible role of serum leptin in preeclampsia. Clin Exp Obstet Gynecol  2016; 43(1): 98-102.
 [PMID: 27048026]

[104]
Asnafi N, Sharbatdaran M, Hajian K. Comparison of maternal and neonatal serum leptin levels in preeclampsia and normal pregnancy. Iran J Reprod Med  2011; 9(2): 131-4.
 [PMID: 25587260]

[105]
Beneventi F, Locatelli E, De Amici M, et al. Maternal and fetal Leptin and interleukin 33 concentrations in pregnancy complicated by obesity and preeclampsia. J Matern Fetal Neonatal Med  2019; 1-7.
 [PMID: 30856361]

[106]
Dorniak-Wall T, Grivell RM, Dekker GA, Hague W, Dodd JM. The role of L-arginine in the prevention and treatment of pre-eclampsia: A systematic review of randomised trials. J Hum Hypertens  2014; 28(4): 230-5.
 [http://dx.doi.org/10.1038/jhh.2013.100] [PMID: 24172291]

[107]
Rizos D, Eleftheriades M, Batakis E, et al. Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby. J Matern Fetal Neonatal Med  2012; 25(8): 1311-5.
 [http://dx.doi.org/10.3109/14767058.2011.632037] [PMID: 22010788]

[108]
Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of Asymmetric Dimethyl Arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand  1998; 77(8): 808-13.
 [PMID: 9776593]

[109]
Ley K. The role of selectins in inflammation and disease. Trends Mol Med  2003; 9(6): 263-8.
 [http://dx.doi.org/10.1016/S1471-4914(03)00071-6] [PMID: 12829015]

[110]
Bosio PM, Cannon S, McKenna PJ, O’Herlihy C, Conroy R, Brady H. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG  2001; 108(7): 709-15.
 [http://dx.doi.org/10.1111/j.1471-0528.2001.00170.x] [PMID: 11467696]

[111]
Laskowska M, Laskowska K, Oleszczuk J. Elevated maternal serum sP-selectin levels in preeclamptic pregnancies with and without intrauterine fetal growth restriction, but not in normotensive pregnancies complicated by isolated IUGR. Med Sci Monit  2013; 19: 118-24.
 [http://dx.doi.org/10.12659/MSM.883780] [PMID: 23416763]

[112]
Dehghani-Firouzabadi R, Tayebi N, Ghasemi N, Tahmasbi Z. The association between second-trimester maternal serum alpha-fetoprotein in 14-22 weeks and adverse pregnancy outcome. Acta Med Iran  2010; 48(4): 234-8.
 [PMID: 21279936]

[113]
Taché V, Baer RJ, Currier RJ, et al. Population-based biomarker screening and the development of severe preeclampsia in California. Obstet Gynecol  2014; 211(4): 377.
 [http://dx.doi.org/10.1016/j.ajog.2014.03.026]

[114]
Khosrowbeygi A, Ahmadvand H. Leptin to adiponectin ratio in preeclampsia. Bangladesh Med Res Counc Bull  2013; 39(1): 18-21.
 [http://dx.doi.org/10.3329/bmrcb.v39i1.15805] [PMID: 23923407]

[115]
Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension  2007; 50(1): 137-42.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.087700] [PMID: 17515455]

[116]
Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble FMS-like tyrosine kinase 1 in preeclampsia. Circulation  2011; 124(8): 940-50.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.111.034793] [PMID: 21810665]

[117]
Drobnjak T, Gizurarson S, Gokina NI, et al. Placental protein 13 (PP13)-induced vasodilation of resistance arteries from pregnant and nonpregnant rats occurs via endothelial-signaling pathways. Hypertens Pregnancy  2017; 36(2): 186-95.
 [http://dx.doi.org/10.1080/10641955.2017.1295052] [PMID: 28524718]

[118]
Gizurarson S, Sigurdardottir ER, Meiri H, et al. Placental protein 13 administration to pregnant rats lowers blood pressure and augments fetal growth and venous remodeling. Fetal Diagn Ther  2016; 39(1): 56-63.
 [http://dx.doi.org/10.1159/000381914] [PMID: 26314825]

[119]
Gizurarson S, Huppertz B, Osol G, Skarphedinsson JO, Mandala M, Meiri H. Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents. Fetal Diagn Ther  2013; 33(4): 257-64.
 [http://dx.doi.org/10.1159/000345964] [PMID: 23406577]
Cite As
Current Women`s Health Reviews

Predictive Biochemical Factors for Pre-eclampsia in Early Pregnancy

Abstract

Graphical Abstract
